The Data-Driven R&D Autobahn to Cures

Global leadership in data, science & access
Disclaimer

This presentation (including any information which has been or may be supplied in writing or orally in connection herewith or in connection with any further inquiries) is being delivered on behalf of Evotec SE (the “Company”, “we,” “our” or “us”). This presentation is made pursuant to Section 5(d) and/or Rule 163B of the Securities Act of 1933, as amended, and is intended solely for investors that are qualified institutional buyers or certain institutional accredited investors solely for the purposes of familiarizing such investors with the Company. This presentation shall not constitute an offer to sell or the solicitation of an offer to buy Evotec securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. No representations or warranties, express or implied, are made as to the accuracy or completeness of the statements, estimates, projections or assumptions contained in the presentation, and neither the Company nor any of its directors, officers, employees, affiliates, agents, advisors or representatives shall have any liability relating thereto.

Cautionary Note Regarding Forward-Looking Statements

This presentation contains forward-looking statements concerning our business, operations and financial performance and condition, as well as our plans, objectives and expectations for our business operations and financial performance and condition. Many of the forward-looking statements contained in this presentation can be identified by the use of forward-looking words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “potential,” “should,” “target,” “would” and other similar expressions that are predictions of or indicate future events and future trends, although not all forward-looking statements contain these identifying words. Forward-looking statements are based on our management’s beliefs and assumptions and on information currently available to our management. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements due to a variety of factors. The forward-looking statements contained in this presentation speak only as of the date of this presentation, and unless otherwise required by law, we do not undertake any obligation to update them in light of new information or future developments or to release publicly any revisions to these statements in order to reflect later events or circumstances or to reflect the occurrence of unanticipated events.

Non-IFRS Measures

This presentation contains references to certain non-IFRS measures including EBITDA and Adjusted EBITDA, each of which are not recognized under International Financial Reporting Standards (“IFRS”). The Company believes that non-IFRS financial information, when taken collectively, may be helpful to investors because it provides consistency and comparability with past financial performance and assists in comparisons with other companies, some of which use similar non-IFRS financial information to supplement their IFRS results. The non-IFRS financial information is presented for supplemental informational purposes only, and should not be considered a substitute for financial information presented in accordance with IFRS, and may be different from similarly titled non-IFRS measures used by other companies. EBITDA and Adjusted EBITDA each have limitations as an analytical tool, respectively, and you should not consider any of these measures either in isolation or as a substitute for other methods of analyzing the results as reported under IFRS. Our management team uses these non-IFRS financial measures to evaluate our profitability and efficiency, to compare operating results to prior periods, and to measure and allocate financial resources internally. However, management does not consider such non-IFRS measures in isolation or as an alternative to measures determined in accordance with IFRS. See appendix to this presentation for a reconciliation of Adjusted EBITDA to the nearest GAAP measure.
Agenda

Unique business strategy and capabilities to improve efficiency

Precision medicine platforms to improve probability of success

Building a strong growth business and a large royalty pool
Unique strategy and capabilities to improve Efficiency & Probabilities of Success
We design medicines for difficult to treat diseases in efficient collaborations.

We focus on data driven precision medicine and early disease relevance to improve Probabilities of Success.

We built the “shared economy” in R&D, designed to result in a large royalty pool.

“\textit{The goal of Evolution is not one single human, it is mankind.}“

\textbf{Manfred Eigen}  
1927–2019, Co-founder of Evotec, Nobel Prize 1967

\textbf{Bringing the industry closer together}  
Our contribution to the industry
Panomics and tech convergence bring up Probability of Success

Current challenges in R&D

<table>
<thead>
<tr>
<th>Key challenges</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>R&amp;D model is inefficient</td>
<td>Challenging returns due to “too late and “expensive failure”</td>
</tr>
<tr>
<td>“One drug fits all” is outdated</td>
<td>90% of drugs are efficacious only in 50% of patients</td>
</tr>
<tr>
<td>New modalities did not solve all problems</td>
<td>9% of Phase I biologics receive approval</td>
</tr>
<tr>
<td>Emerging technologies are still very fragmented</td>
<td>Precision medicine toolkit, OMICS platforms, and AI/ML</td>
</tr>
</tbody>
</table>

**Development costs per asset increase**

- Cost per asset doubled since 2010, in US$ m
- 2010: ~1,188
- 2020: ~2,500
- +100%

**Commercial returns decrease**

- IRR since 20101,4)
- 2010: ~10
- 2020: ~23)
- -80%

---

3) Panomics and tech convergence bring up Probability of Success

1) IRR = Internal Rate of Return
3) excl. Covid-19 vaccines
4) Sources: Deloitte – Centre for Health Solutions: Ten years on measuring the return of pharmaceutical innovation 2020; Evaluate Pharma – World Preview 2018 / World Preview 2020
Significant improvements of Probability of Success are possible

How we can improve Probability of Success (PoS) in early R&D (Examples/simplified)

Todays use of AI/ML

<table>
<thead>
<tr>
<th>Target identification</th>
<th>System biology to better understand diseases e.g. associating existing targets with new diseases</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lead optimisation</td>
<td><em>In silico</em> classification of targets via computational chemistry e.g. better prioritised drugs accelerated</td>
</tr>
<tr>
<td>Trial design</td>
<td>Understanding sub populations via biomarkers e.g. better patient stratification</td>
</tr>
</tbody>
</table>

![Graph showing the impact of AI/ML on Probability of Success](image-url)
Many players at work to initiate a new “data driven” industry paradigm.

Still a highly fragmented industry

Selected AI/ML companies (Industry landscape – Illustrative & highly simplified)
Convergence of precision medicine platforms to improve probability of success
Developing precise medicines with panomics & tech convergence

Overview

Data-driven R&D Autobahn to Cures – combining all relevant parts for an integrated, end-to-end approach

R&D efficiency platforms

Precision medicine platforms

Right modality drug design

Just – Evotec Biologics

EVO\textit{panHunter}
EVO\textit{panOmics}
EVO\textit{gnostic}
\begin{itemize}
\item E.iPSC
\item E.MPD
\item ScreenSeq
\item ScreenPep
\item E.SAFETY
\item E.iBETA
\end{itemize}

EVO\textit{genes}
EVO\textit{cells}
E.O.RNA
Antibodies & Bifunctionals
Antisense
Exosomes
Protein degradation
Small molecules

J.DISCOVERY
J.HAL
J.MD
J.P3
J.POD

Target ID & validation
Chemistry
Biomarker discovery
Integrated pre-clinical development

Hit identification
Bio Reagents
Antibody discovery
Clinical development solution

Lead optimization
Integrated CMC
In vitro biology
Research informatics

In vivo Pharmacology
DDP & ADME-Tox
Sample management
INDIGO

Overview
Continued strong partnerships with precision medicine platforms

Most significant alliances signed in H1 2022

Data-driven R&D Autobahn to Cures

- **Boehringer Ingelheim**: Ophthalmology; iPSC- and **EVOpanOmics**; Undisclosed upfront and milestone payments, layered royalties

- **Bristol Myers Squibb**: Neurodegeneration; iPSC and expansion on target protein degradation

- **Bristol Myers Squibb**: Target protein degradation / molecular glues; **EVOpanOmics** & **EVOpanHunter**; €200 m upfront, €5 bn deal value, tiered royalties

- **Lilly**: Kidney diseases & diabetes; **E.MPD**; **EVOpanOmics**; Undisclosed upfront payment; Five programmes with milestone payments of up to US$180 preprogramme, tiered royalties

- **Janssen**: Protein homeostasis; **TargetAlloMod**; €210 m milestone payment per project, tiered royalties

E.MPD = Molecular patient database
Integrated approach for deeper understanding of diseases

Multi-omics analyses on patient samples combined with iPSC based disease modelling

**Clinical data**
- Patient history
- Diagnostic tests

**Omics data**
- Genomics
- Transcriptomics
- Proteomics
- Metabolomics

**Molecular disease signatures**
**Novel disease targets**

**EPMG**
**E.iPSC**

**Patient cohorts**
Healthy
Disease
- e.g. Kidney Diseases,
  CNS, Women's Health,
  Oncology, Liver Diseases,
  Communicable Diseases

**Evo panOmics**
Data generation

**Evo panHunter**
Data analysis

**Phenotype reversion screening**

'Disease in a dish'

Patient iPSC
Proteomics approach to targeted protein degradation
Development of novel therapies for a broad range of diseases

- May 2020: Screening milestone
- Oct 2020: Project initiation
- Mar 2021: Double-digit million extension
- June 2021: New collaboration in undisclosed therapeutic area
- May 2022: 8-year extension
  - Upfront $200 m
  - Deal value > $5bn

- 2018:
  - Upfront US$ 65 m
  - Potential milestones > US$ 250 m per project
  - Double-digit royalties

- 2019:
  - June 2020: US$ 10 m – Expansion

- 2020:
  - Dec 2020: Second project initiation

- 2021:
  - May 2021: Third project initiation

- 2022:
  - New collaboration in undisclosed therapeutic area

Using EVOpanOmics & EVOpanHunter – Quantum Leap in 2022
### E.MPD core component of alliances in CKD

**CKD strategic drug discovery deals**

<table>
<thead>
<tr>
<th>Year</th>
<th>2016/17</th>
<th>2018/19</th>
<th>2020</th>
<th>2021</th>
<th>2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>Upfront</td>
<td>• Upfront</td>
<td>• Upfront</td>
<td>• Upfront</td>
<td>• Upfront</td>
<td>• Upfront</td>
</tr>
<tr>
<td>Research funding</td>
<td>• Research funding</td>
<td>• Research funding</td>
<td>• Research funding</td>
<td>• Research funding</td>
<td>• Research funding</td>
</tr>
<tr>
<td>Milestones</td>
<td>&gt; € 300 m per product</td>
<td>&gt; € 300 m per product</td>
<td>&gt; € 150 m per product</td>
<td>&gt; € 150 m per product</td>
<td>&gt; € 150 m per product</td>
</tr>
<tr>
<td>Tiered royalties</td>
<td>• Tiered royalties</td>
<td>• Tiered royalties</td>
<td>• Tiered royalties</td>
<td>• Tiered royalties</td>
<td>• Tiered royalties</td>
</tr>
</tbody>
</table>

**From Target identification & validation, via biomarker identification, to patient stratification**

* Pending acquisition by CSL Limited not closed, yet
iPSC already highly productive, …”but just the beginning”

Continuous expansion of disease models and programs to result in new collaborations

Proof of concept in iPSC drug discovery from target ID to clinical development shown for Neurodegenerative Diseases
Delivering health by expanding & improving cell therapy research

Overview H1 2022

- QRBeta 1.0 – First generation cell therapy for Insulin-dependent diabetes
- iPSC-based beta cells combined with Cell Pouch™

- Acquisition of Rigenerand Srl, Medolla, Italy, now operating as Evotec (Modena) Srl
- Evotec Cell Accelerator: cGMP manufacturing as basis for off-the-shelf cell therapies
Transformative iPSC-based disease modelling & cell therapy

Industry leading iPSC platform

Global precision medicine market\(^1\) in US$ bn

<table>
<thead>
<tr>
<th>Year</th>
<th>2020</th>
<th>2025</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>63</td>
<td>107</td>
</tr>
</tbody>
</table>

CAGR ~11%

Global cell therapy market\(^2\) in US$ bn

<table>
<thead>
<tr>
<th>Year</th>
<th>2020</th>
<th>2025</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>7.8</td>
<td>15.7</td>
</tr>
</tbody>
</table>

CAGR ~15%

Global induced pluripotent stem cell (iPSC) Market in US$ bn

<table>
<thead>
<tr>
<th>Year</th>
<th>2020</th>
<th>2025</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>1.6</td>
<td>2.3</td>
</tr>
</tbody>
</table>

CAGR ~7%

“IPS cells are a powerful tool to cure intractable diseases because they can be made from patients’ somatic cells.”
Shinya Yamanaka, Nobel prize laureate

Largest and most sophisticated iPSC platform in the industry

>300 patient-derived cell lines across 15+ disease areas

Optimized for high reproducibility, high throughput and robustness

First iPSC-derived drug candidate entered clinical trials in 2021

EVO cells – Seamlessly integrating discovery, development and cGMP manufacturing

---

\(^1\) [https://www.gmininsights.com/](https://www.gmininsights.com/) Feb 2020, Evotec estimates

\(^2\) [https://www.grandviewresearch.com/industry-analysis/cell-therapy-market](https://www.grandviewresearch.com/industry-analysis/cell-therapy-market), Evotec estimates

# Building a iPSC-based cell therapy pipeline

## Internal off-the-shelf cell therapy programmes

<table>
<thead>
<tr>
<th>Field</th>
<th>Program / Project</th>
<th>Disease area</th>
<th>Exploratory</th>
<th>Pre-clinical research</th>
<th>Pre-clinical development</th>
<th>IND / Phase 1</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Anti-tumour cell therapy</strong></td>
<td>iNK</td>
<td>IO(^1)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>iM</td>
<td>IO</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>γδ iT</td>
<td>IO</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>αβ iT</td>
<td>IO</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Regenerative therapy</strong></td>
<td>E.I.BETA Sernova Cell Pouch(^\text{TM})</td>
<td>Diabetes</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>iCM</td>
<td>Heart failure</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Immune-modulation</strong></td>
<td>iMSCs, iMSC exosomes</td>
<td>Various</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>iNK, iTreg</td>
<td>Anti-fibrotic, auto-immune</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

## iPSC-based cell types

- **iNK**: Natural killer cells
- **iT**: αβ and γδ T cells
- **iM**: Macrophages
- **iBeta**: Pancreatic islets
- **iCM**: Cardiomyocytes
- **iMSC**: Mesenchymal stromal cells

\(^1\) Immuno-oncology
Shaping the value proposition to meet future demand

Just – Evotec Biologics development update

R&D efficiency platforms
Precision medicine platforms
Right modality drug design

Data-driven Autobahn to Cure

J.POD® Toulouse (France) EU: construction work about to start

Number of partnerships and volume of sales order book already doubled in H1 2022 versus 2021; Latest Alpine Immune Sciences extension to design commercial manufacturing process

Just – Evotec Biologics is still in its build up and initial investment phase, but nevertheless on track to meet AP 2025 goals, despite delayed revenues in 2022
Continuous process outperforming fed batch 20x

Large scale production readiness is imminent

Fully end-to-end continuous process for late-stage products (> 25-day production)

Kg DS\(^1\) per Bioreactor

\(^1\) DS = Drug Substance
Programmes of partners with increasing breadth and depth

Just – Evotec Biologics client programmes

<table>
<thead>
<tr>
<th>Disease area</th>
<th>No. of programmes</th>
<th>Discovery</th>
<th>J.MD Optimization</th>
<th>Pre-clinical development</th>
<th>Clinical manufacturing</th>
<th>Commercial Manufacturing</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oncology</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>4</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Autoimmune</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cardiovascular</td>
<td>2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CNS</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Infectious diseases</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>3</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other / undisclosed</td>
<td>ND(1)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>ND</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Broad basis for sustained growth**
- > 15 partners / 18 programmes
- Well balanced partner structure
  - Large / Mid-sized Pharma
  - Large / Small Biotech
  - Foundations
- Continued emphasis on optimal value mix of
  - Fee for service
  - **EVO**royalty
  - **EVO**equity
- Better access to affordable medicine for all
  >50% of programmes addressing targets set to reach UN SDG 3(2)
Strong growth of biologics business

New programme wins and sales orderbook value

- Number of newly signed programmes in 1H2022 already exceeds number during FY 2021
- New contracts carry significantly higher value than in FY 2021
- Progress of projects through development process (discovery, clinical, commercial) and new signings will result in acceleration of business pipeline growth

FY 2021
- New programmes won
- Value of new wins

H1 2022
- New programmes won
- Value of new wins
Building a strong growth business and a large royalty pool
Significant expansion of alliances is basis for long-term success

Attraction, Extension, Retention

- Customer base more diversified; revenues have grown significantly

- Integrated drug discover & development offering yields increasing “share of wallet”
- Faster and better results versus in-house infrastructures

- Solid customer retention rates
- Strong basis for double-digit growth

Attraction

<table>
<thead>
<tr>
<th>Year</th>
<th>New customers during the year</th>
</tr>
</thead>
<tbody>
<tr>
<td>2019</td>
<td>283</td>
</tr>
<tr>
<td>2020</td>
<td>315</td>
</tr>
<tr>
<td>2021</td>
<td>355</td>
</tr>
</tbody>
</table>

Extension

<table>
<thead>
<tr>
<th>Year</th>
<th>No. of customers &gt; € 1 m revenues</th>
</tr>
</thead>
<tbody>
<tr>
<td>2019</td>
<td>2020</td>
</tr>
<tr>
<td>2021</td>
<td>2020</td>
</tr>
</tbody>
</table>

Structural Retention ≥90%

- Customer relation rate
The growing iceberg of product opportunities

>220 projects including EVO equity and BRIDGEs: ~180 in partnerships, >40 internal R&D

<table>
<thead>
<tr>
<th>Neuroscience &amp; Pain</th>
<th>Oncology</th>
<th>Metabolic Diseases</th>
<th>Inflammation &amp; Immunology</th>
<th>Virology</th>
<th>Anti-bacterial</th>
<th>Global Health</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Clinical</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ph3</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Insomnia</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Ph2</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ND</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Ph1</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ND</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Preclinical</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Aeovian</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Exscientia</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Discovery</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>LO</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ND</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>H2L</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ND</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AD/Scr.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ND</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

1) Also includes Women’s Health, Respiratory projects
The Equity Pipeline does not contain programs from EVT/partners that are not publicly disclosed
**Selected pipeline events within next 12 – 24 months**

- Phase III & registration (CHN) JingXin in insomnia (EVT201)
- Phase II data with Bayer in DNP (BAY2395840)
- Phase II initiation with Bayer in Gynaecology (BAY2395840)
- Phase I data in Chikungunya virus (EVT894)
- Phase I data with BMS in CNS (EVT8683)
- Phase I data with Kazia on Oncology (EVT801)
- Phase Ib/II initiation of Exscientia in Oncology (EXS21546)
- Phase I initiation in Covid-19 / HBV (EVT075)
- Phase I initiation with Bayer in Kidney diseases
- Phase I Initiation with Ki:Gen in Kidney diseases with other partners
- Phase I initiation with BMS in CNS
- Phase I initiation with BMS in Oncology
- Multiple co-owned equity companies (not outlined here) will progress in clinic (e.g. Topas, Forge, Carrick, Fibrocor, …)

**Molecule** | **Therapeutic Area/Indication** | **Partner** | **Discovery** | **Pre-clinical** | **Phase I** | **Phase II** | **Phase III**
---|---|---|---|---|---|---|---
EVT201 | Insomnia (GABA-A) | Bayer |  |  |  |  |  
Not disclosed | Infectious Disease (Antibody) | Bayer |  |  |  |  |  
BAY2395840 | Diabetic Neuropathic Pain (B1) | Bayer |  |  |  |  |  
CT7001 | Oncology (CDK7) | Carrick |  |  |  |  |  
XP-105 | Oncology (mTORC1/2) | Exscientia |  |  |  |  |  
EVT401 | Immunology & Inflammation (P2X7) | Exscientia |  |  |  |  |  
BAY2328065 | Gynaecology | Pfizer |  |  |  |  |  
EXS21546 | Oncology (various programmes) | Exscientia |  |  |  |  |  
CXTX 6016 | Pain (CB2) | Exscientia |  |  |  |  |  
EVT894 | Chikungunya (Antibody) | Sanofi |  |  |  |  |  
Not disclosed | Neuroscience & Pain | n.a. |  |  |  |  |  
Not disclosed | Neuroscience & Pain | n.a. |  |  |  |  |  
EVT801 | Oncology (VEGFRI3) | Kazia |  |  |  |  |  
EVT8683 | Neurodegeneration (eIF2b activator) | Bristol Myers Squibb |  |  |  |  |  
TPM203 | Pemphigus Vulgaris (ND) | Topas Therapeutics |  |  |  |  |  
CT7001 | Oncology (CDK7) | Carick |  |  |  |  |  
CT7001 | Oncology (CDK7) | Carick |  |  |  |  |  
APN411 | Oncology – Immunotherapy | Sanofi |  |  |  |  |  
GLPGxxxx | Fibrosis (not disclosed) | Anthera |  |  |  |  |  
BAYxxxx | Nephrology (not disclosed) | Voros |  |  |  |  |  
QBRO01 | Metabolic – Diabetes (not disclosed) | Takeda |  |  |  |  |  
EVT075 | Covid-19 / HBV | n.a. |  |  |  |  |  
Not disclosed | Various programmes | Bristol Myers Squibb |  |  |  |  |  
EVTxxxx | CNS, Metabolic, Pain, … | >10 further programmes |  |  |  |  |  

*Multiple programmes across nephrology, oncology, immunology among other therapeutic areas*
EVO equity accelerates co-owning strategy

Operational VC model - diversified portfolio with multiple shots on goal

At Equity Holding (≥20%) or Significant influence

Minority Shareholdings (<20%)

BRIDGEs

https://actionplan.evotec.com/evoequity
## Guidance refinement – On track towards reaching AP 2025 goal

### Guidance 2022

<table>
<thead>
<tr>
<th></th>
<th>Guidance 2022</th>
<th>YE 2021</th>
<th>Implied growth at midpoint</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Group revenues</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(H1 2022)</td>
<td>€ 715 – 735 m</td>
<td></td>
<td>&gt;15%</td>
</tr>
<tr>
<td>(FY 2021 call)</td>
<td>€ 700 – 720 m</td>
<td>€ 618 m</td>
<td>~15%</td>
</tr>
<tr>
<td>(at constant fx-rates(^1))</td>
<td>(€ 690 – 710 m)</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Unpartnered R&amp;D</strong></td>
<td>€ 70 – 80 m</td>
<td>€ 58 m</td>
<td>~30%</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Adjusted EBITDA</strong></td>
<td>€ 105 – 120 m</td>
<td></td>
<td>At least stable</td>
</tr>
<tr>
<td>(at constant fx-rates; H1 2022)</td>
<td>(€ 85 – 100 m)</td>
<td>€ 107 m</td>
<td></td>
</tr>
<tr>
<td>(at constant fx-rates; FY 2021 call)</td>
<td>(€ 95 – 110 m)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

---

\(^1\) EUR/US$ 1.18; EUR/GBP 0.86
\(^2\) No material FX effects as most R&D efforts are carried out in € area
\(^3\) Excluding M&A related costs and before contingent considerations, income from bargain purchase & excl. impairments on goodwill, other intangible & tangible assets as well as the total non-operating result

---

Approx. € 300 m investment programme for enabling and supporting growth (e.g. capacity expansion, …)
Clear strategy in place

Growth and investment strategy overview – Action Plan 2025

Targeted revenue development
(in € m)

<table>
<thead>
<tr>
<th>Year</th>
<th>2020</th>
<th>2021</th>
<th>2022 (e)</th>
<th>2023 (e)</th>
<th>2024 (e)</th>
<th>2025 (e)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Revenue</td>
<td>501</td>
<td>618</td>
<td>&gt;1,000</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CAGR</td>
<td>~15%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Revenue composition 2020

- EVT Execute: ~70%
- Just – Evotec Biologics¹: ~10%
- EVT Innovate: >20%

Goal revenue composition

- EVT Execute: >40%
- Just – Evotec Biologics¹: >30%
- EVT Innovate: >25%

Key Points:

- Composition of revenue mix expected to change over time while ALL fields continue to grow
- Shifting to even more favourable revenue mix expected to drive increased profitability
- Just – Evotec Biologics growth driven by use of J.POD® manufacturing
- First small royalties from pipeline assets expected in 2025

¹ Just – Evotec Biologics reports under the EVT Execute segment
### Setting the pace to accelerate growth along Action Plan 2025

#### Selected major newsflow 2022

| R&D efficiency platforms | • Undisrupted growth of base business, in-line with AP 2025 (*EvoR&D*)
| | • New integrated drug discovery & development alliances
| | • Significant capacity and value chain expansion for all modalities
| Precision medicine platforms | • New strategic partnerships and expansions of co-owned alliances
| | • New clinical trial initiations
| | • Significant progress of later stage co-owned pipeline (*EvoRoyalty*)
| | • Spin-Offs and investments along Building Blocks of AP 2025 (*EvoEquity*)
| Just – Evotec Biologics | • Start of production J.POD® Redmond, WA (US)
| | • Start of construction J.POD® Toulouse, France (EU)
| | • Evaluation of global network of J.PODs® (*EvoAccess*)
| Group & ESG | • Undisrupted growth trend versus 2021 in line with AP 2025
| | • Growth of unpartnered R&D investments faster than top-line
| | • Validated science-based targets aligned with 1.5°C goal
| | • Highly impactful contribution to UN SDG 3\(^1\)

---

\(^1\)UN Sustainable Development Goal 3: Improve health and well-being with main targets for us on women’s health, fight against infectious diseases and pandemic preparedness
Looking forward to seeing you in person

Financial calendar 2022

<table>
<thead>
<tr>
<th>Event</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Quarterly Statement Q1 2022</td>
<td>11 May 2022</td>
</tr>
<tr>
<td>Virtual Annual General Meeting 2022</td>
<td>22 June 2022</td>
</tr>
<tr>
<td>Half-year 2022 Interim Report</td>
<td>11 August 2022</td>
</tr>
<tr>
<td>Capital Markets Day in Seattle / Redmond</td>
<td>02 November 2022</td>
</tr>
<tr>
<td>Quarterly Statement 9M 2022</td>
<td>09 November 2022</td>
</tr>
</tbody>
</table>
Looking forward to seeing you in Redmond/Seattle

On site at Just – Evotec Biologics

In person and virtual

Capital Markets Day on 02 November 2022
Appendix
Action Plans deliver significant value

Action Plans in numbers - “... we are just at the beginning”

2009
Action Plan 2012
Restructure for growth

2010
- Revenues: € 55 m
- Adj. EBITDA: € 2 m
- R&D investments:1) € 2 m
- Co-owned projects: 6
- Employees: 519

2012
Action Plan 2016
Build innovation seeds

2015
- Revenues: € 128 m
- Adj. EBITDA: € 9 m
- R&D investments:1) € 18 m
- Co-owned projects: 49
- Employees: 1,000

2018
Action Plan 2022
Aspire global leadership

2020
- Revenues: € 501 m
- Adj. EBITDA: € 107 m
- R&D investments:1) € 69 m
- Co-owned projects: 118
- Employees: 3,572

2021
Action Plan 2025
Leadership in data, science, multimodality & access

2025

---

1) Including equity investments
Platforms and panomics technologies for more precision and efficiency

Evotec today – 16 Sites and more than 4,400 employees

USA
- >500
  - Branford
  - Princeton
  - Redmond, WA
  - Seattle
  - Watertown

Austria
- ~40
  - Orth an der Donau

Italy
- >850
  - Verona (Campus Levi-Montalcini)
  - Modena

Germany
- >1,050
  - Hamburg (HQ) & Goettingen (Manfred Eigen Campus)
  - Cologne
  - Munich

UK
- >950
  - Abingdon (Dorothy Crowfoot Hodgkin Campus)
  - Alderley Park

France
- >950
  - Lyon
  - Toulouse (Campus Curie)
Great talent pool

Overview Employees – more than 4,200

Interdisciplinary
- Biochemists
- Medicinal chemists
- Molecular biologists
- Cell biologists
- Toxicologists
- Data scientists
- Process/Analytical chemists
- Clinicians
- mAb process engineers

International
1) The chart exclude the USA for legal reasons
- 22% Others
- 20% German
- 21% French
- 19% Italian
- 18% British

Highly qualified
- 76% with at least one academic qualification
- 24% other degrees

Diverse and experienced
- 84 nationalities
- >30% PhDs
- Average age: 38.5 years
- 54% women
- > 36% with more than five years at Evotec
Our purpose is to go VERY long as ONE – #researchneverstops

Sustainable thinking is holistic and ensures long-term success

Best possible environment for employees and potential recruits
- Engagement & commitment
- Leadership & training
- Diversity, Equity & Inclusion

Resilient business model
- Financial resilience & independence
- Constant investments into the future
- Basis for sustainable success

Acknowledging Principles for Responsible Investment
- Compliance with investors’ sustainable investment criteria
- Source for funding resilient growth

The “shared economy” in R&D
- Integrated platform with >800 partners
- Sharing values of highest integrity
- Sharing success

Cures for all / Access for all
- We will not stop until all existing diseases can be cured
- Precise, patient-centric medicine
- Respecting diversity in all dimensions

Protecting the planet
- Commitment to SBTi \(^1\)
- Responsible use of resources

---

\(^1\) “Science Based Targets Initiative”
Strong team and shareholders supporting sustainable growth

Management & shareholder structure

Management Board
- Werner Lanthaler (CEO)
  Long-time experience in Pharma & biotech
- Cord Dohrmann (CSO)
  Long-time experience in drug discovery
- Matthias Evers (CBO)
  Long-time experience in business development, technology and strategy
- Craig Johnstone (COO)
  Strong drug discovery and commercial track record
- Enno Spillner (CFO)
  Long-time experience in finance & biotech

Supervisory Board
- Iris Löw-Friedrich
  UCB
- Camilla Macapili Languille
  Mubadala Investment Co.
- Mario Polywka
  Ex-Evotec
- Roland Sackers
  QIAGEN
- Elaine Sullivan
  Ex-Lilly
- Constanze Ulmer-Eilfort
  PSP Munich

Number of shares: 177.0 m
Listings: Frankfurt Stock Exchange (MDAX, TecDAX), Ticker: EVT
  NASDAQ Global Select Market (ADS), Ticker: EVO
52 week high/low: € 45.83/€ 20.16

1) Rounding differences may occur
Your contact:

Volker Braun  
*Global Head of Investor Relations & ESG*

+49.(0).40.560 81-775  
+49.(0).151 1940 5058 (m)  
vvolker.braun@evotec.com